Literature DB >> 33424776

Diabetes in Patients With Pancreatic Neuroendocrine Neoplasms.

Xiaoling Zhuge1, Yajie Wang2, Xiao Chen2, Chuangen Guo3.   

Abstract

Objective: Diabetes mellitus (DM) is probably a risk factor for pancreatic neuroendocrine neoplasms (PNENs). However, the prevalence of DM in PNEN patients remains inconclusive. In the present study we observed the prevalence of DM and possible risk factors in PNEN patients.
Methods: After excluding those with insulinoma, a total of 197 patients with PNENs were included. The demographic data, pathological characteristics, and data of blood biochemical tests were recorded. DM was considered if there was evidence of a fasting plasma glucose level of ≥7.0 mmol/L or a 2-h plasma glucose level of ≥11.1 mmol/L, or a history of DM at the time of PNEN diagnosis. Impaired fasting glucose was considered if fasting plasma glucose level was between 6.1 and 7.0 mmol/L.
Results: The prevalence of DM, new-onset DM, and impaired fasting glucose were 17.26, 9.14, and 7.1%, respectively. The prevalence of DM was 26.0% in patients ≥60 years old (19/73) and 12.1% in patients <60 years old. Multivariable logistic regression analysis demonstrated that age, tumor size, and nerve invasion were independent risk factors for DM and impaired fasting glucose + DM (p < 0.05). Age, organs and nerve invasion were independent risk factors for impaired fasting glucose. Low high-density lipoprotein (HDL) was also a risk factor for incident of DM (OR = 0.15, 95%CI: 0.03-0.66). G2/G3 was an independent risk factor for DM in women.
Conclusion: Our data shows that the prevalence of DM is 17.26% in patients with PNENs and is 26.0% in patients ≥60 years of age after excluding insulinoma. Age, nerve invasion, tumor size, and HDL are risk factors for DM in PNEN patients.
Copyright © 2020 Zhuge, Wang, Chen and Guo.

Entities:  

Keywords:  diabetes mellitus; fasting plasma glucose; high-density lipoprotein; pancreatic neuroendocrine neoplasms; tumor grade

Mesh:

Substances:

Year:  2020        PMID: 33424776      PMCID: PMC7786385          DOI: 10.3389/fendo.2020.615082

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  24 in total

1.  Prevalence of diabetes among men and women in China.

Authors:  Wenying Yang; Juming Lu; Jianping Weng; Weiping Jia; Linong Ji; Jianzhong Xiao; Zhongyan Shan; Jie Liu; Haoming Tian; Qiuhe Ji; Dalong Zhu; Jiapu Ge; Lixiang Lin; Li Chen; Xiaohui Guo; Zhigang Zhao; Qiang Li; Zhiguang Zhou; Guangliang Shan; Jiang He
Journal:  N Engl J Med       Date:  2010-03-25       Impact factor: 91.245

Review 2.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

Review 3.  The epidemiology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Ben Lawrence; Bjorn I Gustafsson; Anthony Chan; Bernhard Svejda; Mark Kidd; Irvin M Modlin
Journal:  Endocrinol Metab Clin North Am       Date:  2011-03       Impact factor: 4.741

Review 4.  The management of neuroendocrine tumours: A nutritional viewpoint.

Authors:  Marco Gallo; Giovanna Muscogiuri; Genoveffa Pizza; Rosaria Maddalena Ruggeri; Luigi Barrea; Antongiulio Faggiano; Annamaria Colao
Journal:  Crit Rev Food Sci Nutr       Date:  2017-11-29       Impact factor: 11.176

5.  Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis.

Authors:  Heli Gao; Wenquan Wang; Huaxiang Xu; Chuntao Wu; Wei Jin; Shirong Zhang; Jinzhi Xu; Quanxing Ni; Xianjun Yu; Liang Liu
Journal:  Pancreatology       Date:  2019-03-01       Impact factor: 3.996

Review 6.  Diabetic Neuropathy.

Authors:  Elina Zakin; Rory Abrams; David M Simpson
Journal:  Semin Neurol       Date:  2019-10-22       Impact factor: 3.420

Review 7.  The role of an anti-diabetic drug metformin in the treatment of endocrine tumors.

Authors:  Shilpa Thakur; Brianna Daley; Joanna Klubo-Gwiezdzinska
Journal:  J Mol Endocrinol       Date:  2019-08       Impact factor: 5.098

8.  Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective.

Authors:  Giovanna Muscogiuri; Barbara Altieri; Manuela Albertelli; Andrea Dotto; Roberta Modica; Luigi Barrea; Giuseppe Fanciulli; Tiziana Feola; Roberto Baldelli; Rosaria Maddalena Ruggeri; Marco Gallo; Valentina Guarnotta; Pasqualino Malandrino; Erika Messina; Mary Anna Venneri; Elisa Giannetta; Diego Ferone; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2020-05-28       Impact factor: 3.633

9.  Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms.

Authors:  Marta Sandini; Oliver Strobel; Thomas Hank; Magdalena Lewosinska; Anna Nießen; Thilo Hackert; Markus W Büchler; Simon Schimmack
Journal:  Surgery       Date:  2019-12-27       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.